AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.
At Pfizer, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma.
Amgen focuses on areas of unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
At Boehringer Ingelheim we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.
Bristol Myers Squibb
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.
GSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
Merck is a leading science and technology company in healthcare, life science and performance materials, working to make a positive difference to millions of people’s lives every day. Merck holds the global rights to the Merck name and brand. Exceptions: US and Canada, where the company operates as EMD Serono, MilliporeSigma, EMD Performance Materials, MilliporeSigma and EMD Performance Materials.
Merck Pfizer Alliance
Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance is jointly developing and commercializing avelumab. The alliance is focused on developing high-priority international clinical programs to investigate avelumab as a monotherapy as well as combination regimens, and is striving to find new ways to treat cancer.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Servier is an international pharmaceutical company governed by a non-profit foundation, with a strong international presence in 149 countries.
Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
ArcherDX, LLC is advancing molecular diagnostics with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining patented Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays.
Guardant Health AMEA
Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs.
The Illumina mission is to improve human health by unlocking the power of the genome. Now, through innovation and collaboration, we are enabling genomic breakthroughs in immunotherapy, biomarker discovery, and therapy selection. The opportunity to transform tumor profiling with innovative assays that enable comprehensive genomic profiling, new companion diagnostic development, and liquid biopsy inspires us to push boundaries and drive innovation.
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients diagnosed with cancer. Signatera has been clinically validated in multiple cancer types.
Since 2004, Molecular Health stands for transforming big clinical data into improved treatment decisions. Using our cloud-based Dataome technology platform, we analyze molecular and clinical data of individual patients and compare it to the world’s most up-to-date comprehensive medical, biological, and pharmacological knowledge. Our software products MH Guide, MH Mendel, and MH BRCA enable physicians to take the most informed treatment decisions.
*Information is accurate as of 29 October 2020. Subjected to changes.